Professional Documents
Culture Documents
Rosuvastatin
Rosuvastatin
Rosuvastatin
COLLEGE OF NURSING
DRUG STUDY
Name of Drug Classification Mechanism of Indications and Side Effects Nursing Responsibilities
Action Contraindications (Before, During and After Responsibilities)
Indications: Rosuvastatin is a Common Side Before:
Generic Name: statin medication used as a
lipid-lowering agent. The FDA- Effects: Check the doctor’s order
Rosuvastatin Therapeutic Class: Rosuvastatin is a approved indications are Feeling sick Observe the 5 rights of drug
Antilipemics selective and homozygous familial (nausea) administration
Trade/Brand Name: hypercholesterolemia,
competitive inhibitor of hyperlipidemia, mixed Headaches Assess for another contraindication
Crestor, Ezallor, Roszet Pharmacologic HMG-CoA reductase, the dyslipidemia, primary Stomach pain
Class: HMG-CoA rate-limiting enzyme dysbetalipoproteinemia, Feeling weak or During:
Patient’s Dose: 10mg hypertriglyceridemia, and
that converts -3- prevention of cardiovascular dizzy Instruct patient to take drug exactly
hydroxy-3- disease. The non-FDA-approved Constipation as prescribed
Minimum Dose: 5mg methylglutaryl uses are in non-cardioembolic Protein in your Teach patient about diet, exercise,
stroke, secondary prevention in
coenzyme A to transient ischemic attack (TIA), pee (urine) and weight control
Maximum Dose: mevalonate, a precursor and perioperative therapy for Tell patient to immediately report
40mg of cholesterol. cardiac risk reduction in unexplained muscle pain,
noncardiac surgeries.
tenderness or weakness, especially
Contraindications: if accompanied by malaise or fever.
Instruct patient to take drug at
Pregnancy (pregnancy
category X)
least 2 hours before taking
> There are reports of aluminum or magnesium containing
congenital anomalies antacids.
Breastfeeding
Active liver disease
Unexplained persistent
After:
elevations of serum Educate the patient about the
transaminases possible side effects.
Report severe dizziness, depression
and headache.
Do proper documentation
References:
1.
De Denus S, Spinler SA. Early statin therapy for
acute coronary syndromes. Ann
Pharmacother. 2002 Nov;36(11):1749-
58. [PubMed]
2.
Ray KK, Cannon CP. The potential relevance of
the multiple lipid-independent (pleiotropic)
effects of statins in the management of acute
coronary syndromes. J Am Coll Cardiol. 2005
Oct 18;46(8):1425-33. [PubMed]
3.
Schachter M. Chemical, pharmacokinetic and
pharmacodynamic properties of statins: an
update. Fundam Clin Pharmacol. 2005
Feb;19(1):117-25. [PubMed]